A Multicenter Cross-sectional Study on Mental Health of Patients With Multiple Myeloma

Multiple myeloma patients with normal ability of communication and understanding will be enrolled. DT, GAD-7, PHQ-15 and PSQI scales are designed to assess the mental health status of the patients. Demographic and disease data of patients will be collected as well. The main aim is to explore the factors affecting the mental health of myeloma patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Psychological Distress Behavior Blood Protein Disorders Cardiovascular Diseases Dyssomnias Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Immune System Diseases Immunoproliferative Disorders Insomnia Lymphoproliferative Disorders Medically Unexplained Symptoms Mental Disorders Multiple Myeloma Neoplasms Neoplasms by Histologic Type Neoplasms, Plasma Cell Nervous System Diseases Paraproteinemias Pathological Conditions, Signs and Symptoms Personal Satisfaction Psychological Well-Being Signs and Symptoms Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders Somatic Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

shanghai Jiaotong University School of Medicine, Renji Hospital

Shanghai, Shanghai Municipality, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with symptomatic multiple myeloma were diagnosed according to the criteria of Chinese multiple myeloma diagnosis and treatment guidelines (revised in 2022).
Age ≥18 years, with junior high school education or above. Patients have normal ability of communication and understanding.
Informed consent has been signed.

Exclusion criteria

Who has kinship with other enrolled patients.
Life expectancy of< 6 months.

Treatment and study plan

Primary outcomes

morbidity of psychological distress in patients with multiple myeloma.

Time frame: Baseline (the time when the patient is enrolled to the study)

The total score of DT scale ≥4 points is defined as obviously psychological distress.

Secondary outcomes

morbidity of anxiety in patients with multiple myeloma.

Time frame: Baseline (the time when the patient is enrolled to the study)

GAD-7 scale is applied to assess the anxiety of the patient
morbidity of insomnia in patients with multiple myeloma.

Time frame: Baseline (the time when the patient is enrolled to the study)

PSQI scale is applied to assess the insomnia of the patient

Sponsors and collaborators

Lead sponsor

RenJi Hospital

Other

Registry information

Important dates

Study start: 2022
Primary completion: 2023
Study completion: 2023
First posted: Nov 17, 2022
Registry last updated: Nov 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed